Cost-Effectiveness of Quantiferon®-TB Gold-In-Tube Versus Tuberculin Skin Testing for Contact Screening and Treatment of Latent Tuberculosis Infection in Brazil

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Steffen, Ricardo Ewbank ^a   Caetano, Rosângela ^b   Pinto, Márcia ^c   Chaves, Diogo ^d   Ferrari, Rossini ^d   Bastos, Mayara ^d   de Abreu, Sandra Teixeira ^e   Menzies, Dick ^f   Trajman, Anete ^d,f  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d GAMA FILHO UNIVERSITY   (Brazil)

^e General Hospital of Santa Casa de Misericórdia Do Rio de Janeiro   (Brazil)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

ADULT; ARTICLE; BRAZIL; COHORT ANALYSIS; CONTACT EXAMINATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOKINE RELEASE; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; IMMUNOASSAY; IMMUNOCOMPETENCE; INTERMETHOD COMPARISON; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; PREVALENCE; PROTEIN DETERMINATION; QUANTIFERON TB GOLD IN TUBE; SCREENING TEST; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST;

BRAZIL; CONTACT TRACING; COST-BENEFIT ANALYSIS; DECISION TREES; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MASS SCREENING; MODELS, ECONOMETRIC; TUBERCULIN TEST;

EID: 84875917971     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059546     Document Type: Article

References (50)

1. Raviglione M, Marais B, Floyd K, Lonnroth K, Getahun H, et al. (2012) Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 379: 1902-1913.
2. Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC, (2005) Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 293: 2767-2775.
3. Dye C, Williams BG, (2008) Eliminating human tuberculosis in the twenty-first century. J R Soc Interface 5: 653-662.
4. Menzies D, Gardiner G, Farhat M, Greenaway C, Pai M, (2008) Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results. Int J Tuberc Lung Dis 12: 498-505.
5. International Union Against Tuberculosis Committee on Prophylaxis (1982) Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUATL trial: International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ: 555-564.
6. Comstock GW, (1999) How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 3: 847-850.
7. Trajman A, Long R, Zylberberg D, Dion MJ, Al-Otaibi B, et al. (2010) Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. Int J Tuberc Lung Dis 14: 551-559.
8. Koch R, (1982) Classics in infectious diseases. The etiology of tuberculosis: Robert Koch. Berlin, Germany 1882. Rev Infect Dis 4: 1270-1274.
9. Mantoux M, (1912) La voie intradermique en tuberculinothérapie. Presse Med 20: 146-148.
10. Bierrenbach AL, Cunha SS, Barreto ML, Pereira SM, Rodrigues LC, (2001) Skin test reactivity to mycobacterial antigens parallels the phylogenetic structure of their genus. Int J Tuberc Lung Dis 5: 656-663.
11. Cobelens FG, Menzies D, Farhat M (2007) False-positive tuberculin reactions due to non-tuberculous mycobacterial infections. Int J Tuberc Lung Dis 11: 934-935;author reply 935.
12. Menzies D, (2000) What does tuberculin reactivity after bacille Calmette-Guerin vaccination tell us? Clin Infect Dis 31Suppl 3: S71-74.
13. Huebner RE, Schein MF, Bass JB Jr, (1993) The tuberculin skin test. Clin Infect Dis 17: 968-975.
14. Watkins RE, Brennan R, Plant AJ, (2000) Tuberculin reactivity and the risk of tuberculosis: a review. Int J Tuberc Lung Dis 4: 895-903.
15. Pai M, Zwerling A, Menzies D, (2008) Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149: 177-184.
16. Burgos JL, Kahn JG, Strathdee SA, Valencia-Mendoza A, Bautista-Arredondo S, et al. (2009) Targeted screening and treatment for latent tuberculosis infection using QuantiFERON-TB Gold is cost-effective in Mexico. Int J Tuberc Lung Dis 13: 962-968.
17. de Perio MA, Tsevat J, Roselle GA, Kralovic SM, Eckman MH, (2009) Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. Arch Intern Med 169: 179-187.
18. Deuffic-Burban S, Atsou K, Viget N, Melliez H, Bouvet E, et al. (2010) Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection. Int J Tuberc Lung Dis 14: 471-481.
19. Diel R, Nienhaus A, Loddenkemper R, (2007) Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany. Chest 131: 1424-1434.
20. Diel R, Wrighton-Smith P, Zellweger JP, (2007) Cost-effectiveness of interferon-gamma release assay testing for the treatment of latent tuberculosis. Eur Respir J 30: 321-332.
21. Hardy AB, Varma R, Collyns T, Moffitt SJ, Mullarkey C, et al. (2010) Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the QuantiFERON-TB Gold IGRA alone is more cost-effective for immigrants from high burden countries. Thorax 65: 178-180.
22. Kowada A, Takahashi O, Shimbo T, Ohde S, Tokuda Y, et al. (2008) Cost effectiveness of interferon-gamma release assay for tuberculosis contact screening in Japan. Mol Diagn Ther 12: 235-251.
23. Linas BP, Wong AY, Freedberg KA, Horsburgh Jr CR (2011) Priorities for Screening and Treatment of Latent Tuberculosis Infection in the United States. Am J Respir Crit Care Med.
24. Marra F, Marra CA, Sadatsafavi M, Moran-Mendoza O, Cook V, et al. (2008) Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts. Int J Tuberc Lung Dis 12: 1414-1424.
25. Oxlade O, Schwartzman K, Menzies D, (2007) Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. Int J Tuberc Lung Dis 11: 16-26.
26. Pareek M, Watson JP, Ormerod LP, Kon OM, Woltmann G, et al. (2011) Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis.
27. Pooran A, Booth H, Miller RF, Scott G, Badri M, et al. (2010) Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. BMC Pulm Med 10: 7.
28. Denkinger CM, Dheda K, Pai M, (2011) Guidelines on interferon-gamma release assays for tuberculosis infection: concordance, discordance or confusion? Clin Microbiol Infect 17: 806-814.
29. Programa Nacional de Controle da Tuberculose (2010) Manual de Recomendações para o Controle da Tuberculose no Brasil.
30. Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, et al. (2011) The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practices. PLoS Med 8: e1001012.
31. Morrison J, Pai M, Hopewell PC, (2008) Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis 8: 359-368.
32. Schwartzman K, Menzies D, (2000) Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis. Am J Respir Crit Care Med 161: 780-789.
33. Dowdy DW, Lourenco MC, Cavalcante SC, Saraceni V, King B, et al. (2008) Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults. PLoS One 3: e4057.
34. Steffen R, Menzies D, Oxlade O, Pinto M, de Castro AZ, et al. (2010) Patients' costs and cost-effectiveness of tuberculosis treatment in DOTS and non-DOTS facilities in Rio de Janeiro, Brazil. PLoS One 5: e14014.
35. Slowiak PF, (1985) Life cycle costing in hospitals. How to provide quality systems cost effectively. Hosp Top 63: 31-33.
36. Edejer TT-T, World Health Organization. (2003) Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization. xiii, 312, 318 p.
37. Ministerio da Saúde (2010) Série histórica do número de casos novos de tuberculose. Brasil, Regiões e Unidades Federadas de residência por ano diagnóstico (1990 a 2010).
38. Gold MR (1996) Cost-effectiveness in health and medicine. New York: Oxford University Press. xxiii, 425 p.
39. Salpeter SR, Sanders GD, Salpeter EE, Owens DK, (1997) Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. Ann Intern Med 127: 1051-1061.
40. Mancuso JD, Niebuhr DW, Frick KD, Keep LW, Anderson KM (2011) Cost-effectiveness analysis of targeted and sequential screening strategies for latent tuberculosis. Int J Tuberc Lung Dis 15: 1223-1230, i.
41. Kowada A, (2010) Cost effectiveness of interferon-gamma release assay for tuberculosis screening of rheumatoid arthritis patients prior to initiation of tumor necrosis factor-alpha antagonist therapy. Mol Diagn Ther 14: 367-373.
42. Kowada A, Deshpande GA, Takahashi O, Shimbo T, Fukui T, (2010) Cost effectiveness of interferon-gamma release assay versus chest X-ray for tuberculosis screening of BCG-vaccinated elderly populations. Mol Diagn Ther 14: 229-236.
43. Nolan CM, (2003) Isoniazid for latent tuberculosis infection: approaching 40 and reaching its prime. Am J Respir Crit Care Med 168: 412-413.
44. Tsevat J, Taylor WC, Wong JB, Pauker SG, (1988) Isoniazid for the tuberculin reactor: take it or leave it. Am Rev Respir Dis 137: 215-220.
45. Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, et al. (2011) 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 377: 1588-1598.
46. Pai M, O'Brien R, (2007) Serial testing for tuberculosis: can we make sense of T cell assay conversions and reversions? PLoS Med 4: e208.
47. Lemos AC, Matos ED, Pedral-Sampaio DB, Netto EM, (2004) Risk of tuberculosis among household contacts in Salvador, Bahia. Braz J Infect Dis 8: 424-430.
48. LoBue PA, Moser KS, (2003) Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 168: 443-447.
49. Kopanoff DE, Snider DE Jr, Caras GJ, (1978) Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 117: 991-1001.
50. Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, et al. (2011) Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 37: 88-99.